Who owns Bolt Biotherapeutics, Inc.?
Institutional ownership of BOLT from SEC Form 13F filings across 16 reporting managers. All positions are from one synchronized reporting period — 2026-06-30 books, filed up to 45 days after quarter end — so every row is comparable.
16
13F holders
$606,305
value, 2026 filers
8.2%
of shares outstanding (157,477 sh)
3
new positions (2026 filers)
Top institutional holders
ordered by shares owned · positions as of 2026-06-30· % of fund = share of the manager's own book · % of co. = share of BOLT's shares outstanding
| # | Manager | Shares | Value | % of fund | % of co. | Δ shares QoQ |
|---|---|---|---|---|---|---|
| 1 | CITADEL ADVISORS LLC | 56,903 | $219,077 | 0.0% | 3% | +462.9% |
| 2 | T3 Companies, LLC | 38,000 | $146,300 | 0.2% | 2% | 0.0% |
| 3 | GEODE CAPITAL MANAGEMENT, LLC | 19,119 | $73,622 | 0.0% | 1% | -33.6% |
| 4 | Shay Capital LLC | 15,438 | $59,436 | 0.0% | 0.8% | +3.6% |
| 5 | BlackRock, Inc. | 9,711 | $37,388 | 0.0% | 0.5% | 0.0% |
| 6 | VANGUARD CAPITAL MANAGEMENT LLC | 7,060 | $27,181 | 0.0% | 0.4% | -50.0% |
| 7 | MORGAN STANLEY | 3,145 | $12,108 | 0.0% | 0.2% | -1.4% |
| 8 | VANGUARD FIDUCIARY TRUST CO | 3,095 | $11,916 | 0.0% | 0.2% | 0.0% |
| 9 | NewEdge Advisors, LLCNEW | 2,530 | $9,740 | 0.0% | 0.1% | new |
| 10 | Tower Research Capital LLC (TRC) | 1,710 | $6,584 | 0.0% | 0.1% | +56.5% |
| 11 | MERCER GLOBAL ADVISORS INC /ADVNEW | 292 | $1,124 | 0.0% | 0% | new |
| 12 | UBS Group AG | 255 | $982 | 0.0% | 0% | -67.6% |
| 13 | SBI Securities Co., Ltd. | 130 | $501 | 0.0% | 0% | +1200.0% |
| 14 | JPMORGAN CHASE & CO | 42 | $165 | 0.0% | 0% | 0.0% |
| 15 | CITIGROUP INCNEW | 41 | $158 | 0.0% | 0% | new |
| 16 | BARCLAYS PLC | 6 | $23 | 0.0% | 0% | 0.0% |
Source: SEC Form 13F-HR filings (institutional managers over $100M in US-listed positions). 13Fs disclose long positions only, up to 45 days after quarter end; each manager's latest filed quarter is shown per row and dollar values are the manager's filed marks. Aggregates labeled "2026 filers" count only managers whose latest book is a 2026 quarter. Related: valuation · options positioning · supply chain. Research, not investment advice.